EP0504136A4 - Tolerogenic immunoglobulin-protein conjugates - Google Patents

Tolerogenic immunoglobulin-protein conjugates

Info

Publication number
EP0504136A4
EP0504136A4 EP19900902970 EP90902970A EP0504136A4 EP 0504136 A4 EP0504136 A4 EP 0504136A4 EP 19900902970 EP19900902970 EP 19900902970 EP 90902970 A EP90902970 A EP 90902970A EP 0504136 A4 EP0504136 A4 EP 0504136A4
Authority
EP
European Patent Office
Prior art keywords
tolerogenic
immunoglobulin
protein conjugates
conjugates
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900902970
Other languages
English (en)
Other versions
EP0504136A1 (de
Inventor
Halina Borel
Yves Borel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Borel Yves
BOREL, HALINA
Original Assignee
Immune Disease Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Disease Institute Inc filed Critical Immune Disease Institute Inc
Publication of EP0504136A1 publication Critical patent/EP0504136A1/de
Publication of EP0504136A4 publication Critical patent/EP0504136A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP19900902970 1989-12-07 1989-12-07 Tolerogenic immunoglobulin-protein conjugates Withdrawn EP0504136A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1989/005539 WO1991008773A1 (en) 1989-12-07 1989-12-07 Tolerogenic immunoglobulin-protein conjugates

Publications (2)

Publication Number Publication Date
EP0504136A1 EP0504136A1 (de) 1992-09-23
EP0504136A4 true EP0504136A4 (en) 1994-06-29

Family

ID=22215409

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900902970 Withdrawn EP0504136A4 (en) 1989-12-07 1989-12-07 Tolerogenic immunoglobulin-protein conjugates

Country Status (3)

Country Link
EP (1) EP0504136A4 (de)
JP (1) JPH05502854A (de)
WO (1) WO1991008773A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE331438T1 (de) * 1995-01-17 2006-07-15 Brigham & Womens Hospital Rezeptorspezifischer transepithelealer transport von immunogenen
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
EP1118335A1 (de) * 2000-01-11 2001-07-25 Aventis Behring GmbH Verfahren zur Herstellung von Konjugate zur Behändlung von Allergien und Autoimmunkrankheiten
EP1118334A1 (de) 2000-01-11 2001-07-25 Aventis Behring Gesellschaft mit beschränkter Haftung Verfahren zur Herstellung von Konjugate zur Behändlung von Allergien und Autoimmunkrankheiten
CA2524615A1 (en) * 2003-05-12 2004-11-18 Tolerogen, Ltd. Immunoglobulin conjugates of autoantigens and their use in the prevention of disease
WO2011036467A1 (en) * 2009-09-24 2011-03-31 Russell David Keenan Products useful in the treatment of haemophilia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4388441A (en) * 1977-02-03 1983-06-14 Scripps Clinic & Research Foundation Induction of immunological tolerance
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
D.T. GOLAN ET AL.: "NONANTIGENICITY AND IMMUNOLOGIC TOLERANCE: THE ROLE OF THE CARRIER IN THE INDUCTION OF TOLERANCE TO THE HAPTEN", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 134, no. 4, 1971, pages 1046 - 1061 *
E.S. RECTOR ET AL.: "A METHOD FOR THE PREPARATION OF PROTEIN-PROTEIN CONJUGATES OF PREDETERMINED COMPOSITION", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 24, no. 1-2, 1978, pages 321 - 336 *
H. BOREL ET AL.: "A NOVEL TECHNIQUE TO LINK EITHER PROTEINS OR PEPTIDES TO GAMMAGLOBULIN TO CONSTRUCT TOLEROGENS", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 126, 1990, pages 159 - 168 *
I.M. NILSSON ET AL.: "INDUCTION OF SPLIT TOLERANCE AND CLINICAL CURE IN HIGH-RESPONDING HEMOPHILIACS WITH FACTOR IX ANTIBODIES", PROC. NATL. ACAD. SCI., vol. 83, 1986, pages 9169 - 9173 *
K.S. TSE ET AL.: "SYNTHESIS OF TOLEROGENIC CONJUGATES FOR SUPPRESSION OF IGE ANTIBODIES TO PROTEIN ALLERGENS", THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 61, no. 3, 1978, pages 180 *
See also references of WO9108773A1 *
T. BARKAS ET AL.: "EXPERIMENTAL MYASTHENIA GRAVIS IS INHIBITED BY RECEPTOR-ANTIRECEPTOR COMPLEXES", J. CLIN. LAB. IMMUNOL., vol. 7, no. 3, 1982, pages 223 - 227 *
Y. BOREL: "NATURAL IMMUNOLOGIC TOLERANCE AND THE CONSTRUCTION OF TOLEROGENS TO TREAT AUTOIMMUNE DISEASES", THERAPY OF AUTOIMMUNE DISEASES.CONCEPTS IMMUNOPATHOL., vol. 7, 1989, BASEL, pages 145 - 161 *

Also Published As

Publication number Publication date
EP0504136A1 (de) 1992-09-23
WO1991008773A1 (en) 1991-06-27
JPH05502854A (ja) 1993-05-20

Similar Documents

Publication Publication Date Title
GB8903313D0 (en) Conjugates
ZA879473B (en) Immunoglubolin conjugates
GB8908250D0 (en) Formulations
IL92230A0 (en) Antibody-drug conjugates
EP0405242A3 (en) Vip-analogs ii
GB2239189B (en) Water-actuated novelty
GB2232681B (en) Nitro-p-phenylenediamine derivatives
GB8919661D0 (en) Superoxide dismutase-catalase conjugates
AP9000174A0 (en) Antiparasitical formulations
ZA89524B (en) Antibody conjugates
GB9003724D0 (en) Toychest ii
EP0430866A3 (en) Connection piece
IL92583A0 (en) Tolerogenic immunoglobulin-protein conjugates
GB9026229D0 (en) Tolerogenic conjugates for suppressing immune responses
AU5090290A (en) Tolerogenic immunoglobulin-protein conjugates
NZ238953A (en) Antibody-superantigen conjugates
IE883489L (en) Drug-monoclonalantibody conjugates
IE893616L (en) Antibody-drug conjugates
EP0453452A4 (en) Vaccine
GB9017729D0 (en) Conjugates
GB8625461D0 (en) Conjugates
GB8927373D0 (en) Tolerogenic conjugates for suppressing immune responses
AU2600688A (en) Oligonucleotide-polyamide conjugates
ZA907863B (en) Vaccine conjugate
GB8922917D0 (en) Formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910607

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19940506

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19941206

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOREL, HALINA

Owner name: BOREL, YVES

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BOREL, HALINA

Inventor name: BOREL, YVES

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950417